FOLD
Amicus TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
FOLD Profile
Amicus Therapeutics, Inc.
A biotech company that develops small molecule drugs to treat Fabry, Gaucher and Pompe diseases
Biological Technology
02/04/2002
05/31/2007
NASDAQ Stock Exchange
499
12-31
Common stock
47 Hulfish Street, Princeton, NJ 08542
--
Amicus Therapeutics, Inc., was incorporated under the laws of the State of Delaware on February 4, 2002. The company is a global, patient-centric biotechnology company focused on discovering, developing and delivering new drugs for rare diseases. The company seeks to provide the highest quality therapies that have the potential to phase out current therapies, provide significant benefits to patients, and become first class or first class. The two therapies the company has marketed are Galafold, the first oral monotherapy for Fabry disease patients with compliant gene variants, and Pombiliti + Opfolda, a novel therapy designed to increase active enzyme uptake in key disease-related tissues in adults with late-onset Pompe disease.
